Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis
An erratum to this article was published (Ann Intern Med, Oct 2023 ↗)
Main finding · ICER per QALY gained (base case, VA Federal Supply Schedule prices)Result — go to the resultICER $493 246Authors' conclusion
The 3 DOACs are more effective and more cost-effective than LMWH. The most cost-effective DOAC depends on the relative cost of each of these agents.
Study context
- Population
- Adults with cancer at the time they develop thrombosis (cancer-associated thrombosis)
- Exposure
- Direct oral anticoagulants (DOACs) vs low-molecular-weight heparin (LMWH)
- Outcome
- ICER in 2022 US dollars per QALY gained
- Follow-up
- Lifetime
Methodological detailscohort-state transition decision analytic model, lifetime horizon, health care sector perspective, data from network meta-analysis, 2022 US dollars, Assumed indefinite anticoagulation unless major bleed; nonmedical costs and long-term thrombotic complications not modelled
- Cohort-state transition decision analytic model
- Lifetime horizon
- Health care sector perspective
- Data from network meta-analysis
- 2022 US dollars
- Assumed indefinite anticoagulation unless major bleed; nonmedical costs and long-term thrombotic complications not modelled
Main finding
As reported in the abstract
ICER per QALY gained (base case, VA Federal Supply Schedule prices)
Incremental cost-effectiveness ratio (ICER)
$493 246
Observational data: associations, not effects.
Further findings
| Outcome | ICER (per QALY) |
|---|---|
| ICER, scenario analysis with GoodRx real-world drug pricesCost-effective | $50 053 |
Probabilistic sensitivity analysis
- Apixaban preferred at willingness-to-pay $50 000 per quality-adjusted life-year (QALY) (share of simulations)
- 80%
- Apixaban cost-effective only if monthly medication costs below; above, rivaroxaban cost-effective
- $530
- Results highly sensitive to monthly drug costs
Original publication
Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis. Ann Intern Med. Published 27 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →